相似文献
1
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).
J Subst Abuse Treat. 2021 Sep;128:108389. doi: 10.1016/j.jsat.2021.108389. Epub 2021 Apr 8.
2
Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Drug Alcohol Depend. 2019 Jan 1;194:482-486. doi: 10.1016/j.drugalcdep.2018.10.035. Epub 2018 Dec 3.
3
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Contemp Clin Trials. 2015 Mar;41:110-7. doi: 10.1016/j.cct.2015.01.005. Epub 2015 Jan 17.
4
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166-0.
5
Extended-release naltrexone for youth with opioid use disorder.
J Subst Abuse Treat. 2021 Nov;130:108407. doi: 10.1016/j.jsat.2021.108407. Epub 2021 Apr 15.
6
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
J Subst Abuse Treat. 2021 Sep;128:108241. doi: 10.1016/j.jsat.2020.108241. Epub 2020 Dec 11.
7
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
J Subst Abuse Treat. 2021 May;124:108292. doi: 10.1016/j.jsat.2021.108292. Epub 2021 Jan 16.
8
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
J Subst Abuse Treat. 2022 Nov;142:108852. doi: 10.1016/j.jsat.2022.108852. Epub 2022 Jul 30.
9
A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
J Subst Abuse Treat. 2020 Oct;117:108076. doi: 10.1016/j.jsat.2020.108076. Epub 2020 Jul 6.
10
Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Addict Sci Clin Pract. 2020 Apr 22;15(1):15. doi: 10.1186/s13722-020-00188-5.
引用本文的文献
1
Sustained-release naltrexone for opioid dependence.
Cochrane Database Syst Rev. 2025 May 9;5(5):CD006140. doi: 10.1002/14651858.CD006140.pub3.
2
Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC).
Health Justice. 2025 Apr 8;13(1):22. doi: 10.1186/s40352-025-00333-9.
3
Considerations when prescribing opioid agonist therapies for people living with HIV.
Expert Rev Clin Pharmacol. 2024 Jul;17(7):549-564. doi: 10.1080/17512433.2024.2375448. Epub 2024 Jul 4.
4
Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative.
PLoS One. 2024 Jun 17;19(6):e0305165. doi: 10.1371/journal.pone.0305165. eCollection 2024.
5
Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non-Clinicians.
Psychiatr Res Clin Pract. 2023 Aug 15;5(3):78-83. doi: 10.1176/appi.prcp.20230022. eCollection 2023 Fall.
6
The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV.
Drug Alcohol Depend Rep. 2023 Apr 14;7:100159. doi: 10.1016/j.dadr.2023.100159. eCollection 2023 Jun.
7
Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States.
Drug Alcohol Depend Rep. 2022 Dec 16;6:100130. doi: 10.1016/j.dadr.2022.100130. eCollection 2023 Mar.
8
The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study.
Health Justice. 2022 Dec 19;10(1):35. doi: 10.1186/s40352-022-00199-1.
9
Use of long-acting injectable buprenorphine in the correctional setting.
J Subst Abuse Treat. 2022 Nov;142:108851. doi: 10.1016/j.jsat.2022.108851. Epub 2022 Jul 29.
10
Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.
Int J Qual Stud Health Well-being. 2022 Dec;17(1):2094111. doi: 10.1080/17482631.2022.2094111.
本文引用的文献
1
A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
J Subst Abuse Treat. 2020 Oct;117:108076. doi: 10.1016/j.jsat.2020.108076. Epub 2020 Jul 6.
2
A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?
Am J Addict. 2020 Jul;29(4):249-267. doi: 10.1111/ajad.13051. Epub 2020 Apr 29.
3
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.
4
Cross-sectional validation of the PROMIS-Preference scoring system.
PLoS One. 2018 Jul 31;13(7):e0201093. doi: 10.1371/journal.pone.0201093. eCollection 2018.
5
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052.
6
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634.
7
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14.
8
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206.
9
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.
10
Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.
Drug Alcohol Depend. 2015 Nov 1;156:133-138. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7.
Zotero 插件